January 15, 2019

Division of Dockets Management (HFA-305)
Food and Drug Administration
5630 Fishers Lane, Room 1061
Rockville, MD 20852

Re: Docket No. FDA-2013-P-0163 – Request for Withdrawal of Citizen Petition

Dear Sir or Madam:

On behalf of Teva Pharmaceutical Industries Ltd., Teva Women's Health, Inc. ("Teva") requests withdrawal of the above-referenced citizen petition requesting that FDA refrain from approving any abbreviated new drug application referencing Paragard T 380A (intrauterine copper contraceptive).

Should you have any questions, please feel free to contact me at rachel.turow@tevapharm.com or 202-531-4780.

Sincerely,

Rachel Turow
Executive Counsel – Regulatory Law
Teva Pharmaceutical Industries Ltd.